Evidence map›Paper›PMID 40034067›Full record

ArticleMicrobial biotechnology2025

Enabling Access to Novel Bacterial Biosynthetic Potential From ONT Draft Genomic Data.

Marco A Campos-Magaña, Vitor A P Martins Dos Santos, Luis Garcia-Morales

Abstract read
In one paragraph

Article in Microbial biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Marco A Campos-MagañaDept. Bioprocess Engineering, Wageningen University and Research, Wageningen, the Netherlands.ORCID https://orcid.org/0009-0009-1379-1140
Vitor A P Martins Dos SantosDept. Bioprocess Engineering, Wageningen University and Research, Wageningen, the Netherlands.ORCID https://orcid.org/0000-0002-2352-9017
Luis Garcia-MoralesLifeglimmer GmbH, Berlin, Germany.ORCID https://orcid.org/0000-0002-3037-4519

Funding

BIOS 101070281CONACYT
6 · The paper itself

Abstract

Natural products comprise a wide diversity of compounds with a range of biological activities, including antibiotics, anti-inflammatory and anti-tumoral molecules. However, we can only access a small portion of these compounds due to various technical difficulties. We have herein developed a novel and efficient approach for accessing biosynthetic gene clusters (BGCs) that encode natural products from soil bacteria. The pipeline uses a combination of long-read sequencing, antiSMASH for BGC identification and Transformation-associated recombination (TAR) for cloning the BGCs. We hypothesized that a genome assembly using Oxford Nanopore Technology (ONT) sequencing could facilitate the detection of large BGCs at a relatively fast and low-cost DNA sequencing. Despite the relative low accuracy and sequence mistakes due to high GC content and sequence repetitions frequently found in BGC containing bacteria, we demonstrate that ONT long-read sequencing and antiSMASH are effective for identifying novel BGCs and enabling TAR cloning to isolate the BGC in a desired vector. We applied this pipeline on a previously non-sequenced myxobacteria Aetherobacter fasciculatus SBSr002. Our approach enabled us to clone a previously unknown BGC into a genome engineering-ready vector, illustrating the capabilities of this powerful and cost-effective strategy.

Indexed as

Biological ProductsBiosynthetic PathwaysGenome, BacterialMyxococcalesNanopore SequencingCloning, MolecularGenomicsMultigene FamilySequence Analysis, DNASoil MicrobiologyBiological Productsbioinformaticsmicrobial genomicsnatural productssecondary metabolitessynthetic biology

Identifiers

PMID40034067
PMCPMC11876861

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.